Diabetes Drug Significantly Reduces Heart Failure Risk in Genetic Carriers
New research published in Nature Medicine reveals that the medication dapagliflozin significantly reduces the risk of heart failure in patients who carry specific cardiomyopathy-associated genetic variants. Findings from the Mass General Brigham Heart and Vascular Institute and the Broad Institute of MIT and Harvard suggest that these genetic markers could help clinicians identify patients who … Read more